NEW YORK – A University of Pennsylvania-led team has published details from a Phase III trial demonstrating that the FLT3 inhibitor gilteritinib (Astellas Pharma's Xospata) can significantly extend average survival in individuals with relapsed or refractory forms of acute myeloid leukemia (AML) containing FLT3 gene mutations.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.